Healthcare

Artrya (ASX:AYA) has moved from a niche cardiac-AI story to one of the more closely watched small-cap healthcare names on the ASX. The shares had risen roughly 247% over the year to 13 August 2026, but the stock also pulled back around 20% over …

Ansell (ASX:ANN) has held up comparatively well through a choppy period for the broader Australian market. With the shares trading near the upper end of their 52-week range in mid-August, attention is shifting to the company’s FY26 full-year results on 24 August 2026. The …

Vitrafy Life Sciences (ASX:VFY) has expanded its U.S. blood-sector presence through a partnership with Hoxworth Blood Center to trial its cryopreservation technology for red blood cells.

SomnoMed (ASX:SOM) has announced aLeadershiptransition alongside the controlled global rollout of Virtus, a new oral appliance designed for patients with obstructive sleep apnoea (OSA) and sleep bruxism.

Argent BioPharma (ASX:RGT) has expanded its exclusive global licensing agreement for CannEpil® to include veterinary applications, creating an additional potential royalty stream alongside the existing human-use arrangement.

Percheron Therapeutics (ASX:PER) has completed a keyManufacturingmilestone for its lead cancer immunotherapy candidate HMBD-002, confirming that a newly manufactured drug substance batch has passed quality testing and can support the company's planned return to clinical trials.

PolyNovo (ASX:PNV) has closed FY26 with group revenue of $150.0 million and a return to positive free cash flow, supported by continued expansion of its NovoSorb wound-care product range and record U.S. sales.